by Brian Shilhavy

Editor, Health Impact News

In the wake of yesterday’s measles “emergency” declaration in Rockland County, New York that prompted the county to implement the nation’s first ban on unvaccinated children from appearing in public places, news reports out of Philadelphia today reveal that over 100 students have been infected with mumps, in spite of the fact that almost all of the students have been vaccinated against it.

Ironically, it is the same vaccine, the MMR (mumps, measles, rubella) vaccine that is being mandated in Rockland County to fight measles.

ABC6 in Philadelphia reports:

Temple University will hold the first of two scheduled vaccination clinics Wednesday, as the number of mumps cases affecting the campus community continues to rise. There are now 105 cases, 18 confirmed, and the rest are probable. These new numbers reflect just how fast this outbreak is spreading. The university is encouraging students, staff, and faculty to get these boosters Wednesday at Temple University’s Mitten Hall. Again this is a virus that spreads through close contacts, like kissing and sharing of utensils. It’s also important to note, most of those who got the mumps were vaccinated. Doctors say MMR vaccine often weakens as people hit their teens or early 20s, but the best defense against the spread is the vaccine.

The fact that doctors are admitting that the MMR vaccine “weakens” as children become teens and adults in their early 20s, calls into question the rationale being used in Rockland County, New York to only require children under the age of 18 to receive the MMR vaccine.

Are MMR Vaccinated People Spreading the Disease Unwittingly?

Perhaps an even bigger concern about these mass MMR vaccination efforts is whether or not those just vaccinated are themselves spreading the diseases of mumps and measles, since it is a “live” vaccine?

The MMR vaccine package insert found on the FDA.gov website states:

Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination.

However, they (Merck Pharmaceutical) then downplay the risk:

There is no confirmed evidence to indicate that such virus is transmitted to susceptible persons who are in contact with the vaccinated individuals. Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk. However, transmission of the rubella vaccine virus to infants via breast milk has been documented (see Nursing Mothers). There are no reports of transmission of live attenuated measles or mumps viruses from vaccinees to susceptible contacts. (Source.)

While this vaccine information sheet is on the FDA.gov website, it was written by the manufacturer of the MMR vaccine, Merck.

The last statement that there are “no reports of transmission of live attenuated measles or mumps viruses from vaccinees to susceptible contacts” seems to be in dispute.

A 2017 study published in the Journal of Clinical Microbiology reported that during the 2015 Disneyland Measles outbreak, it was determined that 73 of the 194 measles cases were from the vaccine:

During the measles outbreak in California in 2015, a large number of suspected cases occurred in recent vaccinees. Of the 194 measles virus sequences obtained in the United States in 2015, 73 were identified as vaccine sequences (R. J. McNall, unpublished data). (Source.)

Rebecca J. McNall, a co-author of this study, is a CDC official in the Division of Viral Diseases. So the CDC has the data proving that some measles outbreaks are, at least in part, caused by the vaccine.

So why hasn’t the FDA required Merck to update their MMR Package Insert to provide accurate information?

Those in the field of medicine know full well that live vaccines have a problem of “shedding” and that recently vaccinated people can spread the very virus being vaccinated for, as is clearly seen on visitor guidelines in hospitals where immune compromised patients reside.

Is the MMR Vaccine Effective? Whistleblowers Who Developed the Vaccine Say “No” in Fraud Lawsuit

In a lawsuit against Merck that was originally filed in 2010, and continues to this day, Stephen Krahling and Joan Wlochowski, former Merck virologists, claim that they “witnessed firsthand the improper testing and data falsification in which Merck engaged to artificially inflate the (MMR) vaccine’s efficacy findings.”

The former Merck scientists claim that Merck’s faulty MMR vaccine has caused the United States to pay “hundreds of millions of dollars for a vaccine that does not provide adequate immunization.”

“As the largest single purchaser of childhood vaccines (accounting for more than 50 percent of all vaccine purchases), the United States is by far the largest financial victim of Merck’s fraud,” according to the 2010 False Claims Act complaint. “But the ultimate victims here are the millions of children who every year are being injected with a mumps vaccine that is not providing them with an adequate level of protection. And while this is a disease that, according to the Centers for Disease Control (‘CDC’), was supposed to be eradicated by now, the failure in Merck’s vaccine has allowed this disease to linger, with significant outbreaks continuing to occur.” (Source.)

See:

Merck has tried, unsuccessfully, to end this case for almost eight years now, in an attempt to hide it from the American public.

Can We Trust the FDA and CDC to Provide Reliable Vaccine Information?



It is a well-established fact that there is a revolving door between the Pharmaceutical industry and government health agencies such as the FDA and CDC.

Dr. Raeford Brown, a pediatric anesthesia specialist at the UK Kentucky Children’s Hospital, also chairs the Food and Drug Administration (FDA) Committee on Analgesics and Anesthetics.

He has stated publicly that “Congress is owned by pharma.” See:

Once a vaccine is approved by the FDA, the CDC can then add it to their schedule of childhood recommended vaccines.

The CDC is tasked with overseeing vaccine safety, but they are also the world’s largest purchaser of vaccines, spending over $5 billion of American taxpayer funds to purchase vaccines from pharmaceutical companies. See:

Are Precautions and Warnings From the Package Insert Being Communicated to Parents and Students Prior to Vaccination?

In the ABC6 report regarding the mumps outbreak at Temple University, reporter Bob Brooks interviews student Syndey Cox who was standing in line to get her MMR vaccine, and she states:

I am a childcare provider, so I have a 4-year-old and I can’t take any risks giving kids mumps.

Given how many students were being shuttled through the clinic to receive the MMR vaccine, we wonder if students like Sydney are given copies of the package insert and are aware of all the warnings and possible adverse effects?

As we have already shown, the MMR is a live vaccine, so does Ms. Cox know she will carry a risk of infecting the children she is concerned about that is prompting her to receive the vaccine?

Do people receiving the MMR vaccine know that brain injuries and death are known side effects, for example?

As a service to the public, Health Impact News is going to publish this information from Merck’s MMR vaccine insert, which is public knowledge and is on the FDA.gov website.

This information is also required by law to be given to individuals prior to vaccination.

Remember, this information is provided by the drug company manufacturing the vaccine (Merck for MMR). We have already shown above that a published study contradicts one of their assertions that the vaccine virus is not spread to others.

CONTRAINDICATIONS Hypersensitivity to any component of the vaccine, including gelatin.{40} Do not give M-M-R II to pregnant females; the possible effects of the vaccine on fetal development are unknown at this time. If vaccination of postpubertal females is undertaken, pregnancy should be avoided for three months following vaccination (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females and PRECAUTIONS, Pregnancy). Anaphylactic or anaphylactoid reactions to neomycin (each dose of reconstituted vaccine contains approximately 25 mcg of neomycin). Febrile respiratory illness or other active febrile infection. However, the ACIP has recommended that all vaccines can be administered to persons with minor illnesses such as diarrhea, mild upper respiratory infection with or without low-grade fever, or other low-grade febrile illness.{41} Patients receiving immunosuppressive therapy. This contraindication does not apply to patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. Primary and acquired immunodeficiency states, including patients who are immunosuppressed in association with AIDS or other clinical manifestations of infection with human immunodeficiency viruses;{41-43} cellular immune deficiencies; and hypogammaglobulinemic and dysgammaglobulinemic states. Measles inclusion body encephalitis{44} (MIBE), pneumonitis{45} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated. WARNINGS Due caution should be employed in administration of M-M-R II to persons with a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided. The physician should be alert to the temperature elevation which may occur following vaccination (see ADVERSE REACTIONS). Hypersensitivity to Eggs Live measles vaccine and live mumps vaccine are produced in chick embryo cell culture. Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after receiving vaccines containing traces of chick embryo antigen. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases. Such individuals may be vaccinated with extreme caution, having adequate treatment on hand should a reaction occur (see PRECAUTIONS).{46} However, the AAP has stated, “Most children with a history of anaphylactic reactions to eggs have no untoward reactions to measles or MMR vaccine. Persons are not at increased risk if they have egg allergies that are not anaphylactic, and they should be vaccinated in the usual manner. In addition, skin testing of egg-allergic children with vaccine has not been predictive of which children will have an immediate hypersensitivity reaction…Persons with allergies to chickens or chicken feathers are not at increased risk of reaction to the vaccine.”{47} Hypersensitivity to Neomycin The AAP states, “Persons who have experienced anaphylactic reactions to topically or systemically administered neomycin should not receive measles vaccine. Most often, however, neomycin allergy manifests as a contact dermatitis, which is a delayed-type (cell-mediated) immune response rather than anaphylaxis. In such persons, an adverse reaction to neomycin in the vaccine would be an erythematous, pruritic nodule or papule, 48 to 96 hours after vaccination. A history of contact dermatitis to neomycin is not a contraindication to receiving measles vaccine.”{47} Thrombocytopenia Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia with the first dose of M-M-R II (or its component vaccines) may develop thrombocytopenia with repeat doses. Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases (see ADVERSE REACTIONS). PRECAUTIONS General Adequate treatment provisions, including epinephrine injection (1:1000), should be available for immediate use should an anaphylactic or anaphylactoid reaction occur. Special care should be taken to ensure that the injection does not enter a blood vessel. Children and young adults who are known to be infected with human immunodeficiency viruses and are not immunosuppressed may be vaccinated. However, vaccinees who are infected with HIV should be monitored closely for vaccine-preventable diseases because immunization may be less effective than for uninfected persons (see CONTRAINDICATIONS).{42,43} Vaccination should be deferred for 3 months or longer following blood or plasma transfusions, or administration of immune globulin (human).{47} Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination. There is no confirmed evidence to indicate that such virus is transmitted to susceptible persons who are in contact with the vaccinated individuals. Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk.{33} However, transmission of the rubella vaccine virus to infants via breast milk has been documented (see Nursing Mothers). There are no reports of transmission of live attenuated measles or mumps viruses from vaccinees to susceptible contacts. It has been reported that live attenuated measles, mumps and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin test is to be done, it should be administered either before or simultaneously with M-M-R II. Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine;{48} no studies have been reported to date of the effect of measles virus vaccines on untreated tuberculous children. However, individuals with active untreated tuberculosis should not be vaccinated.As for any vaccine, vaccination with M-M-R II may not result in protection in 100% of vaccinees. The health-care provider should determine the current health status and previous vaccination history of the vaccinee. The health-care provider should question the patient, parent, or guardian about reactions to a previous dose of M-M-R II or other measles-, mumps-, or rubella-containing vaccines. Information for Patients The health-care provider should provide the vaccine information required to be given with each vaccination to the patient, parent, or guardian. The health-care provider should inform the patient, parent, or guardian of the benefits and risks associated with vaccination. For risks associated with vaccination see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS. Patients, parents, or guardians should be instructed to report any serious adverse reactions to their health-care provider who in turn should report such events to the U.S. Department of Health and Human Services through the Vaccine Adverse Event Reporting System (VAERS), 1-800-822-7967.{49} Pregnancy should be avoided for 3 months following vaccination, and patients should be informed of the reasons for this precaution (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females, CONTRAINDICATIONS, and PRECAUTIONS, Pregnancy). Immunosuppressive Therapy The immune status of patients about to undergo immunosuppressive therapy should be evaluated so that the physician can consider whether vaccination prior to the initiation of treatment is indicated (see CONTRAINDICATIONS and PRECAUTIONS). The ACIP has stated that “patients with leukemia in remission who have not received chemotherapy for at least 3 months may receive live virus vaccines. Short-term (<2 weeks), low- to moderate-dose systemic corticosteroid therapy, topical steroid therapy (e.g. nasal, skin), long-term alternate-day treatment with low to moderate doses of short-acting systemic steroid, and intra-articular, bursal, or tendon injection of corticosteroids are not immunosuppressive in their usual doses and do not contraindicate the administration of [measles, mumps, or rubella vaccine].”{33,34,37} Immune Globulin Administration of immune globulins concurrently with M-M-R IImay interfere with the expected immune response.{33,34,47} Carcinogenesis, Mutagenesis, Impairment of Fertility M-M-R II has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility. Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with M-M-R II. It is also not known whether M-M-R II can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, the vaccine should not be administered to pregnant females; furthermore, pregnancy should be avoided for 3 months following vaccination (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females and CONTRAINDICATIONS). In counseling women who are inadvertently vaccinated when pregnant or who become pregnant within 3 months of vaccination, the physician should be aware of the following: (1) In a 10-year survey involving over 700 pregnant women who received rubella vaccine within 3 months before or after conception (of whom 189 received the Wistar RA 27/3 strain), none of the newborns had abnormalities compatible with congenital rubella syndrome;{50} (2) Mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion. Although mumps vaccine virus has been shown to infect the placenta and fetus, there is no evidence that it causes congenital malformations in humans;{37} and (3) Reports have indicated that contracting wild-type measles during pregnancy enhances fetal risk. Increased rates of spontaneous abortion, stillbirth, congenital defects and prematurity have been observed subsequent to infection with wild-type measles during pregnancy.{51,52} There are no adequate studies of the attenuated (vaccine) strain of measles virus in pregnancy. However, it would be prudent to assume that the vaccine strain of virus is also capable of inducing adverse fetal effects. Nursing Mothers It is not known whether measles or mumps vaccine virus is secreted in human milk. Recent studies have shown that lactating postpartum women immunized with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants.{53} In the infants with serological evidence of rubella infection, none exhibited severe disease; however, one exhibited mild clinical illness typical of acquired rubella.{54,55} Caution should be exercised when M-M-R II is administered to a nursing woman. Pediatric Use Safety and effectiveness of measles vaccine in infants below the age of 6 months have not been established (see also CLINICAL PHARMACOLOGY). Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established. Geriatric Use Clinical studies of M-M-R II did not include sufficient numbers of seronegative subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. ADVERSE REACTIONS The following adverse reactions are listed in decreasing order of severity, without regard to causality, within each body system category and have been reported during clinical trials, with use of the marketed vaccine, or with use of monovalent or bivalent vaccine containing measles, mumps, or rubella: Body as a Whole Panniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability. Cardiovascular System Vasculitis. Digestive System Pancreatitis; diarrhea; vomiting; parotitis; nausea. Endocrine System Diabetes mellitus. Hemic and Lymphatic System Thrombocytopenia (see WARNINGS, Thrombocytopenia); purpura; regional lymphadenopathy; leukocytosis. Immune System Anaphylaxis and anaphylactoid reactions have been reported as well as related phenomena such as angioneurotic edema (including peripheral or facial edema) and bronchial spasm in individuals with or without an allergic history. Musculoskeletal System Arthritis; arthralgia; myalgia. Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children. This type of involvement as well as myalgia and paresthesia, have also been reported following administration of MERUVAXII. Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed chronic joint symptoms. Following vaccination in children, reactions in joints are uncommon and generally of brief duration. In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (children: 0-3%; women: 12-26%),{17,56,57} and the reactions tend to be more marked and of longer duration. Symptoms may persist for a matter of months or on rare occasions for years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and in adult women. Even in women older than 35 years, these reactions are generally well tolerated and rarely interfere with normal activities. Nervous System Encephalitis; encephalopathy; measles inclusion body encephalitis (MIBE) (see CONTRAINDICATIONS); subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); acute disseminated encephalomyelitis (ADEM); transverse myelitis; febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia.Encephalitis and encephalopathy have been reported approximately once for every 3 million doses of M-M-R II or measles-, mumps-, and rubella-containing vaccine administered since licensure of these vaccines. The risk of serious neurological disorders following live measles virus vaccine administration remains less than the risk of encephalitis and encephalopathy following infection with wild-type measles (1 per 1000 reported cases).{58,59} In severely immunocompromised individuals who have been inadvertently vaccinated with measles-containing vaccine; measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infection have been reported (see CONTRAINDICATIONS). In this population, disseminated mumps and rubella vaccine virus infection havealso been reported. There have been reports of subacute sclerosing panencephalitis (SSPE) in children who did not have a history of infection with wild-type measles but did receive measles vaccine. Some of these cases may have resulted from unrecognized measles in the first year of life or possibly from the measles vaccination. Based on estimated nationwide measles vaccine distribution, the association of SSPE cases to measles vaccination is about one case per million vaccine doses distributed. This is far less than the association with infection with wild-type measles, 6-22 cases of SSPE per million cases of measles. The results of a retrospective case-controlled study conducted by the Centers for Disease Control and Prevention suggest that the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its inherent higher risk of SSPE.{60} Cases of aseptic meningitis have been reported to VAERS following measles, mumps, and rubella vaccination. Although a causal relationship between the Urabe strain of mumps vaccine and aseptic meningitis has been shown, there is no evidence to link Jeryl Lynn™ mumps vaccine to aseptic meningitis. Respiratory System Pneumonia; pneumonitis (see CONTRAINDICATIONS); sore throat; cough; rhinitis. Skin Stevens-Johnson syndrome; erythema multiforme; urticaria; rash; measles-like rash; pruritis. Local reactions including burning/stinging at injection site; wheal and flare; redness (erythema); swelling; induration; tenderness; vesiculation at injection site; Henoch-Schönlein purpura; acute hemorrhagic edema of infancy. Special Senses — Ear Nerve deafness; otitis media. Special Senses — Eye Retinitis; optic neuritis; papillitis; retrobulbar neuritis; conjunctivitis. Urogenital System Epididymitis; orchitis. Other Death from various, and in some cases unknown, causes has been reported rarely following vaccination with measles, mumps, and rubella vaccines; however, a causal relationship has not been established in healthy individuals (see CONTRAINDICATIONS). No deaths or permanent sequelae were reported in a published post-marketing surveillance study in Finland involving 1.5 million children and adults who were vaccinated with M-M-R II during 1982 to 1993.{61} Under the National Childhood Vaccine Injury Act of 1986, health-care providers and manufacturers are required to record and report certain suspected adverse events occurring within specific time periods after vaccination. However, the U.S. Department of Health and Human Services (DHHS) has established a Vaccine Adverse Event Reporting System (VAERS) which will accept all reports of suspected events.{49} A VAERS report form as well as information regarding reporting requirements can be obtained by calling VAERS 1-800-822-7967.

Comment on this article at VaccineImpact.com.

Book – The Vaccine Court “The Dark Truth of America’s Vaccine Injury Compensation Program” ORDER HERE!

Say NO to Mandatory Vaccines T-Shirt

100% Pre-shrunk Cotton

Order here!

Make a Statement for Health Freedom!

Big Pharma and government health authorities are trying to pass laws mandating vaccines for all children, and even adults.

Show your opposition to forced vaccinations and support the cause of Vaccine Impact, part of the Health Impact News network.

Order here!